title: Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.
abstract: BACKGROUND
  Erythropoietin (EPO) has been found to have anti-apoptotic and tissue protective effects on the myocardium. The aim of the present pilot study was to observe the safety and efficacy of EPO administration for patients with acute myocardial infarction (AMI).
  
  
  RESULTS
  Patients admitted with AMI had all undergone successful percutaneous coronary intervention (PCI). Patients were randomly assigned to 2 groups (control and EPO groups), and given 12,000 IU EPO iv or saline after PCI. The primary endpoints were the difference between the acute phase and chronic phase (6 months after the attack) regarding left ventricular function as measured on electrocardiogram-gated single-photon emission computed tomography. Thirty-six patients (control 16, EPO 20) were eligible for analysis. Left ventricular ejection fraction (LVEF) significantly increased in the EPO group (from 51.0+/-19.6% to 58.5+/-15.0%, P=0.0238), but not in the control group. Further analysis was separately undertaken in patients with occlusion in the left anterior descending artery (LAD) and others (non-LAD). LVEF was <50% in most patients in the LAD subgroup, and LVEF significantly increased in the EPO group (37.5+/-13.0 to 52.7+/-15.8, P=0.0049), but not in the control group. EPO administration did not trigger any adverse clinical events.
  
  
  CONCLUSIONS
  EPO administration is a promising treatment for AMI.
authors.affiliation: First Department of Internal Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.
authors.forename: Takuya
authors.initials: T
authors.lastname: Ozawa
authors.forename: Ken
authors.initials: K
authors.lastname: Toba
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Kiminori
authors.initials: K
authors.lastname: Kato
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Iso
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Akutsu
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Youichi
authors.initials: Y
authors.lastname: Takeyama
authors.forename: Naohiko
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Norihiko
authors.initials: N
authors.lastname: Yoshimura
authors.forename: Kohei
authors.initials: K
authors.lastname: Akazawa
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D064420:Drug-Related Side Effects and Adverse Reactions; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010865:Pilot Projects; D011994:Recombinant Proteins; D013318:Stroke Volume / Q000187:drug effects; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left; D016277:Ventricular Function, Left
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin